CP-316,311   Click here for help

GtoPdb Ligand ID: 10377

Synonyms: compound 2 [PMID: 18260619] | CP-316311 | CP316311
Compound class: Synthetic organic
Comment: CP-316,311 is an orally active, small molecule corticotropin releasing factor-1 (CRF-1) receptor antagonist [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 1
Hydrogen bond donors 0
Rotatable bonds 6
Topological polar surface area 31.35
Molecular weight 327.22
XLogP 5.92
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCC(Oc1cc(C)nc(c1C)Oc1c(C)cc(cc1C)C)CC
Isomeric SMILES CCC(Oc1cc(C)nc(c1C)Oc1c(C)cc(cc1C)C)CC
InChI InChI=1S/C21H29NO2/c1-8-18(9-2)23-19-12-16(6)22-21(17(19)7)24-20-14(4)10-13(3)11-15(20)5/h10-12,18H,8-9H2,1-7H3
InChI Key ZSEJGVQTBLJRCQ-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
CP-316,311 was advanced to Phase 2 clinical evaluation as a therapy for major depressive disorder, but trial NCT00143091 was terminated because interim analysis showed that the CP-316,311 group failed to show significant benefit compared to the placebo group on the primary endpoint, and that continuation was futile.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT00143091 Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Major Depressive Disorder Phase 2 Interventional Pfizer